Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

NEW YORK and PALO ALTO, Calif., Sept. 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho" or "the Company") today announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement, and customary closing conditions. If completed, the transaction would position Klotho as a leader in the development of longevity therapeutics.

Read more at prnewswire.com